Hemispherx Biopharma | HEB | Profile | Summary

Hemispherx Biopharma (HEB) is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx’s flagship products include Alferon N Injection® and the experimental immunotherapeutics/antivirals Ampligen®.

Hemispherx’s platform technology includes large and small agent components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has an extensive number of patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection®). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in New Brunswick, New Jersey.

ALFERON

Alferon N Injection® is the company's registered trademark for its injectable formulation of Natural Alpha Interferon, and is approved by the FDA for a category of STD infection.  Alferon N Injection® (interferon alfa-n3 human leukocyte derived) is a highly purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon.

Alferon LDO® (Low Dose Oral) is a new experimental drug delivery platform for the Company’s highly purified, natural source alpha interferon.

ALFERON N Injection® is the only highly purified, natural-source, multispecies alpha interferon product currently sold in the U.S. and is also approved for sale in Argentina.

Clinically Effective:

• All warts disappeared in 54% of patients.³

• No recurrence in 76% of complete responders at follow-up.³

• Completely cleared 73% of all treated warts.^3,4

• No human antibodies to interferon alfa-n3 detected in clinical trails.^3,4

• Provides a spectrum of multiple alpha interferon subtypes.^1,

What's in the Pipeline?

Ampligen® (poly I:poly C₁₂U) is a synthetic specifically configured double-stranded RNA containing regularly occurring regions of mismatching.  Ampligen® and Oragens® experimental nucleic acids are being developed for the potential treatment of globally important viral diseases and disorders of the immune system including HPV, HIV, Chronic Fatigue Syndrome (CFS), Hepatitis and influenza.

Watch This!

On July 31, 2012 Hemispherx submitted its complete response to the FDA’s Complete Response Letter in support of Ampligen®’s New Drug Application for Chronic Fatigue Syndrome (“CFS”).

Its too early to tell what the FDA's response would be, however, the response from investors has been very positive. We alerted our members and followers last week and we believe this company should be on your radar!

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®

we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

A123 Systems |AONE | Profile | Summary

A123 Systems – AONE - develops and manufactures advanced Nanophosphate^® lithium iron phosphate batteries and energy storage systems. The company’s technology enables customers to commercialize innovative products for the transportation, electric grid, commercial and government markets.

A123's proprietary Nanophosphate technology is built on novel nanoscale materials initially developed at the Massachusetts Institute of Technology. The company has spent more than $2 billion dollars on development and large scale manufacturing plants with global ambitions.

IronPhosphate Battery Technology

A123’s high-performance Nanophosphate^® lithium iron phosphate (LiFePO4) battery technology delivers high power and energy density combined with excellent safety performance and extensive life cycling in a lighter weight, more compact package. Our products have low capacity loss and impedance growth over time, allowing our systems to meet end-of-life power and energy requirements with minimal pack oversizing.

Lithium Ion Battery Technology

A123’s next-generation Nanophosphate EXT™ lithium ion battery technology improves power capability at low temperature and life at high temperature, potentially reducing or eliminating the need for costly thermal management.

By extending the capabilities of our core Nanophosphate® technology over a wider temperature operating range, Nanophosphate EXT is expected to deliver increased performance and reliability while minimizing complexity and reducing total cost of ownership (TCO) over the life of the battery system for a number of applications, including micro hybrid vehicles, electric vehicles, telecommunications backup and military systems, among others.

Energy Storage Systems

A123 Systems excels at designing and manufacturing fully-integrated battery systems that help enable our customers to take new products from concept to commercialization. A123 has extensive engineering experience in developing and implementing advanced components, software, electronics, thermal management and battery management systems for innovations in battery system design. We provide complete system design and integration services and develop optimized systems that meet our customer’s performance requirements, including power, safety, life, and energy, while meeting size, weight and cost targets.

The Opportunity

The recession in the United States and European Economic crisis resulted in slower than expected demand for the Electric Vehicles. The company is poised to benefit when the global economic conditions improve, it has invested hundreds of millions in R&D and established long term relationships with leading OEMs and built a network of charging stations.

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®

we received or expecting compensation from the featured company. Our firm, principals and staff may own/buy/sell/trade stock/securities of this company. Always Read the full Disclosure/Disclaimer. Thanks.

Epic (EPOR) Market Summary

Epic is a publicly traded company, since its founding in 1997, the company has focused on Research and Development of Healthcare products. Epic's goal is to make a meaningful difference in the lives of millions of Americans who are suffering from chronic pains.

(Note:-OxBridge has just released a comprehensive Market Intelligence Report on EPOR) see the full Report

AcuFABTM

The company has successfully developed a specially engineered fabric called AcuFABTM, which improves blood circulation to the pressure points and sore joints, providing great comfort and relief from chronic pains.

EPIC sells 'the fabric' to the Original Equipment Manufacturers (OEMs), these manufacturers make, various products using the AcuFabTM, and sell directly to consumers and healthcare institutions under their own Brand names.

AcuPADTM

EPIC also makes its own Branded products, with AcuFABTM, under the name AcuPADTM. AcuPADs are sold directly to healthcare institutions and consumers through the company's website www.epiccor.com, Amazon.com and other distributors.

Business Model

Epic’s business model is similar to Intel’s famous “intel inside” model, where Intel supplies CPUs to companies like Dell and HP and these OEMs incorporate intel’s technology into their PCs and Laptops.

The Opportunity

Epic Corporation has a proprietary and patent protected manufacturing process for a fabric solution which offers great advantages to the surface tissue. In a world where we have major problems with sedentary lifestyles, poor eating habits, and healthcare issues, these solutions may be the answer for patients everywhere. What is most intriguing is that these products have some technological barriers to entry yet do not have to go through the rigorous FDA approval process.

Epic's Solutions for Healthcare Crisis

American healthcare system is under severe strain and the healthcare costs are rising rapidly, Obesity and Diabetes increasing dramatically due to diet and sedentary life style. EPIC’s preventative solutions for chronic pains could provide relief from pain and financial burden.

read the full Report